AreteiaTx
Karen Conway, DNP, MBA, RN, currently serves as the Clinical Trial Liaison Manager at AreteiaTx since November 2023. With extensive experience in the medical sciences field, Karen has held various roles including Medical Science Liaison at The Medical Affairs Company (TMAC) focusing on idiopathic pulmonary fibrosis and Senior Medical Science Liaison at Renalytix, concentrating on chronic kidney disease in type 2 diabetes. Previous positions also include multiple liaison and educator roles within oncology and chronic kidney disease therapeutic areas at organizations such as Syneos Health and inVentiv Health Clinical. Furthermore, Karen has a strong clinical research background with experience as a Clinical Research Nurse at Yale University School of Medicine. Academically, Karen is pursuing a Doctorate of Nursing Practice at Quinnipiac University, holds an MBA from the University of New Haven, and earned a BSN in Nursing from the University of Bridgeport.
This person is not in any offices
AreteiaTx
Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication ofimproving lung function and is found in several asthma-related treatments.